Financial Performance Highlights
Q2 FY27 Performance:
- Revenue grew 30% YoY to ₹358 Cr (₹362 Cr net revenue from operations)
- EBITDA grew 26% YoY to ₹52 Cr (₹39 Cr standalone, plus ₹13 Cr JV share)
- EBITDA margin remained healthy
- PAT stood at ₹24 Cr with PAT margin of 6.5%
- EPS of ₹3.5
H1 FY27 Performance:
- Revenue increased 26% YoY to ₹713 Cr (₹720 Cr net revenue from operations)
- EBITDA grew 25% to ₹113 Cr (₹79 Cr standalone, plus ₹33 Cr JV share)
- EBITDA margin stable at 15.8%
- PAT of ₹56 Cr with PAT margin of 7.8%
- EPS of ₹8.4
Business Segment Performance
Bio-based Specialty Materials:
- H1 revenue increased 43% YoY to ₹382 Cr
- Q2 revenue grew 42% YoY to ₹194 Cr
- H1 EBITDA up 15% to ₹62 Cr
- Q2 EBITDA increased 12% YoY to ₹28 Cr
- Margin pressures due to increased costs and freight
- Represents 55% of H1 revenue (up from 52% previously)
Sustainable & Performance Chemicals:
- Q2 revenue grew 36% YoY to ₹167 Cr
- H1 revenue grew 29% to ₹313 Cr
- Q2 EBITDA increased 49% to ₹24 Cr
- H1 EBITDA increased 40% to ₹51 Cr
- Q2 margin expanded from 13.0% to 14.2% (124 bps improvement)
- H1 margin expanded from 15.0% to 16.3%
Demerger Completion
The company completed its demerger into three listed entities:
- India Glycols Limited: Continuing as pure-play chemicals business with FY26 revenue of ₹1,164 Cr and EBITDA of ₹169 Cr (14.5% margin)
- IGL Spirits Limited: Spirits & Bio-fuels business with FY26 revenue of ₹2,801 Cr and EBITDA of ₹492 Cr (17.6% margin)
- Ennature Biopharma Limited: Nutraceuticals & plant-based APIs with FY26 revenue of ₹246 Cr and EBITDA of ₹29 Cr (11.9% margin)
Share allocation: 1 IGL Spirits share for every 1 IGL share, 1 Ennature Biopharma share for every 3 IGL shares.
Operating Environment Impact
Key external factors affecting Q2 performance:
- Brent crude increased from ~$72 to $98
- Gulf supply shortages lifted ether and MEG prices temporarily
- Input costs rose significantly: chemicals up 35-75%, drums and IBCs up 21-54%, freight approximately doubled
- Bio-MEG price gap narrowed to about 2.5 times petro-MEG
- Currency movements: Won up 14%, yen weak, INR near record low
- Domestic challenges: Weak monsoon, gas rationing, RBI rate rise
Balance Sheet Position (as at September 2026)
- Fixed Assets: ₹1,256 Cr
- CWIP: ₹114 Cr
- Trade Receivables: ₹76 Cr
- Cash and Bank Balance: ₹15 Cr
- Inventories: ₹554 Cr
- Total Assets: ₹2,611 Cr
- Shareholders' Fund: ₹1,258 Cr
- Long Term Borrowings: ₹341 Cr
- Short Term Borrowings: ₹484 Cr
Cash Flow Statement (H1 FY27)
- Cash Flow from Operating Activities: ₹39 Cr
- Cash Flow from Investing Activities: (₹95) Cr
- Cash Flow from Financing Activities: ₹35 Cr
- Net decrease in Cash: (₹21) Cr
- Closing Cash Balance: ₹6 Cr
Business Outlook and Strategy
- Positioned as largest bio-based specialty chemicals manufacturer globally
- Structural shift towards specialty-led portfolio with higher value products
- Strong growth visibility from customer additions and product innovation
- Beneficiary of favorable industry dynamics and supply constraints in global markets
- Performance chemicals emerging as key growth driver
- Margin expansion expected through portfolio mix improvement
- Novel technologies in development: CCUS, novel catalysis, CO₂ valorisation
Manufacturing and Operational Capabilities
- Integrated 300-acre Kashipur manufacturing complex
- Direct rail connectivity to ports (~1,500 km to Mundra, Pipavav, Nhava Sheva)
- ~35% of cargo routed via ICD Kashipur
- Multi-source feedstock flexibility
- Backward integration with captive intermediates
- Biomass cogeneration and zero-liquid-discharge operations